Gold is 2025’s best performer. UBS sees more upside
Investing.com - Hologic (NASDAQ: HOLX) reported third quarter EPS of $1.08, $0.03 better than the analyst estimate of $1.05. Revenue for the quarter came in at $1.02B versus the consensus estimate of $1.01B.
Guidance
Hologic sees Q4 2025 EPS of $1.09-$1.12 versus the analyst consensus of $1.07.
Hologic sees Q4 2025 revenue of $1.03B-$1.04B versus the analyst consensus of $1.03B.
Hologic sees FY 2025 EPS of $4.23-$4.26 versus the analyst consensus of $4.18.
Hologic sees FY 2025 revenue of $4.08B-$4.09B versus the analyst consensus of $4.07B.
Hologic’s stock price closed at $65.00. It is up 20.01% in the last 3 months and down -20.35% in the last 12 months.
Hologic saw 0 positive EPS revisions and 16 negative EPS revisions in the last 90 days. See Hologic’s stock price’s past reactions to earnings here.
According to InvestingPro, Hologic’s Financial Health score is "great performance".
Check out Hologic’s recent earnings performance, and Hologic’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar